Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.
- Why Operational Readiness Is The Missing Piece In Biosimilar Adoption
- Demonstrating Non-Inferiority Of BFPCs Vs. Traditional Air Monitoring
- Exploring Takeda's Template For Sustainable Steam Generation
- Transforming Computer System Validation In The Life Sciences Industry
- Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
- Achieving Annex 1 Compliance In Sterile Manufacturing, Part 3: Building A Compliant Program
- An Open-Source Modeling Tool For Suspended Continuous Lyophilization
GUEST COLUMNISTS
-
Why Operational Readiness Is The Missing Piece In Biosimilar Adoption
Biosimilar success depends on seamless execution. Strong care coordination, patient education, and operational readiness are essential to improve access, adherence, and outcomes.
-
Demonstrating Non-Inferiority Of BFPCs Vs. Traditional Air Monitoring
Demonstrating non-inferiority of bio-fluorescent particle counter (BFPC) technology to traditional active air-sampling methods is essential for implementation. Here's how to approach it.
-
Exploring Takeda's Template For Sustainable Steam Generation
Takeda designed a model for delivering steam at 11 bar and up to 184 degrees using natural refrigerant and waste heat at one of its largest production sites.
-
Transforming Computer System Validation In The Life Sciences Industry
Regulators acknowledge how traditional CSV methods fail to meet modern demands for speed and flexibility. The scene is changing in favor of smarter, leaner validation.
-
Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
Since every sponsor–CDMO relationship can have widely different scopes, requirements, and procedures, this article focuses on the basic principles for analyzing and managing the risks of not achieving the relationship’s objectives.
-
Achieving Annex 1 Compliance In Sterile Manufacturing, Part 3: Building A Compliant Program
In this third and final article of this series, let's take a closer look at what a well-constructed Annex 1-compliant program looks like at each stage, from gap assessment through governance.
-
An Open-Source Modeling Tool For Suspended Continuous Lyophilization
Building on a continuous suspended-vial lyophilization workflow, process developers can model critical variables before doing physical experiments.
BIOSIMILAR WHITE PAPERS
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.
-
The Role Of Extractables Data In The Adoption Of Single-Use Systems8/29/2024
Explore guidance for evaluating single-use systems for extractables and leachables, and learn how supplier-provided single-use system extractables data can save both time and resources.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Why Biopharma Breakthroughs Aren't Moving The Market10/20/2025
Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.
-
2024 Global Biopharma Sustainability Review9/3/2024
What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies setting the standard?
-
Process Analytical Technology In The ADC Bioconjugation Process4/23/2025
Integrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.
BIOSIMILAR APP NOTES & CASE STUDIES
- Ultra-Low Cross-Linked Microgel Purification
- CDMO Uses Robotic Gloveless Isolator For Advanced Therapeutics
- Selecting A Platform Filter For High Concentration mAbs
- Improving Bioprocess Monitoring And Control With Multivariate Data Analysis
- Evaluation Of Extractables And Physical Compatibility Of The Mobius® ADC Reactor Single-Use Components For ADC Manufacturing
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Samsung Bioepis Launches OPUVIZ (Aflibercept) 40 mg/mL Pre-Filled Syringe Across Europe
- Amneal Completes Acquisition Of Kashiv BioSciences, Creating A Global Biosimilar Leader
- Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection For Its Denosumab Injections
- Kyungdong Pharmaceutical And Asimov Announce Completion Of Cell Line Development Campaign For Biosimilar Antibody
- Biocon Announces U.S. Commercial Launch Of Yesafili, A Biosimilar To Regeneron's Eylea 2 mg
- Fresenius Announces FDA Approval Of Rituximab Biosimilar For The U.S. Market
- Polpharma Biologics Announces FDA And EMA Acceptance For Review Of PB016 Vedolizumab Biosimilar Candidate
- Meitheal Pharmaceuticals Announces FDA Approval Of Garzulys (insulin aspart-fsan) Injection
NEWSLETTER ARCHIVE
- 08.06.26 -- Achieving Annex 1 Compliance In Sterile Manufacturing
- 07.30.26 -- FDA Explains How To Respond To Form 483 Observations
- 07.23.26 -- Solving Glycoengineering Challenges Could Begin At The Cell Line
- 07.16.26 -- Is Your AI Model Trustworthy & Credible In GMP Processes
- 07.09.26 -- Affinity Membranes Are Moving Closer To Commercial Reality